The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Intracellular Domains of CXCR3 That Mediate CXCL9, CXCL10, and CXCL11 Function
Open accessAbstract
The chemokine receptor CXCR3 is a G protein-coupled receptor found predominantly on T cells that is activated by three ligands as follows: CXCL9 (Mig), CXCL10 (IP-10), and CXCL11 (I-TAC). Previously, we have found that of the three ligands, CXCL11 is the most potent inducer of CXCR3 internalization and is the physiologic inducer of CXCR3 internalization after T cell contact with activated endothelial cells. We have therefore hypothesized that these three ligands transduce different signals to CXCR3. In light of this hypothesis, we sought to determine whether regions of CXCR3 are differentially required for CXCL9, CXCL10, and CXCL11 function. Here we identified two distinct domains that contributed to CXCR3 internalization. The carboxyl-terminal domain and beta-arrestin1 were predominantly required by CXCL9 and CXCL10, and the third intracellular loop was predominantly required by CXCL11. Chemotaxis and calcium mobilization induced by all three CXCR3 ligands were dependent on the CXCR3 carboxyl terminus and the DRY sequence in the third trans-membrane domain. Our findings demonstrate that distinct domains of CXCR3 mediate its functions and suggest that the differential requirement of these domains contributes to the complexity of the chemokine system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chemokines — Chemotactic Cytokines That Mediate Inflammation
Luster, A. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380706 · Cited by 3,630
Self-citationβ-Arrestin-Dependent Formation of β 2 Adrenergic Receptor-Src Protein Kinase Complexes
Luttrell, L. M., Ferguson, S. S. G., Daaka, Y., Miller, W. E., Maudsley, S., Della Rocca, G. J., Lin, F.-T., Kawakatsu, H., Owada, K., Luttrell, D. K., et al. (1999) · Science · doi:10.1126/science.283.5402.655 · Cited by 1,475
Heterotrimeric C proteins: Organizers of transmembrane signals
Neer, E. J. (1995) · Cell · doi:10.1016/0092-8674(95)90407-7 · Cited by 1,405
Qin, S., Rottman, J. B., Myers, P., Kassam, N., Weinblatt, M., Loetscher, M., Koch, A. E., Moser, B., & Mackay, C. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1422 · Cited by 1,359
Loetscher, M., Gerber, B., Loetscher, P., Jones, S. A., Piali, L., Clark-Lewis, I., Baggiolini, M., & Moser, B. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.963 · Cited by 1,193
Dufour, J. H., Dziejman, M., Liu, M. T., Leung, J. H., Lane, T. E., & Luster, A. D. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3195 · Cited by 1,075
Self-citationRole of β-Arrestin in Mediating Agonist-Promoted G Protein-Coupled Receptor Internalization
Ferguson, S. S. G., Downey, W. E., Colapietro, A.-M., Barak, L. S., Ménard, L., & Caron, M. G. (1996) · Science · doi:10.1126/science.271.5247.363 · Cited by 972
Cole, K. E., Strick, C. A., Paradis, T. J., Ogborne, K. T., Loetscher, M., Gladue, R. P., Lin, W., Boyd, J. G., Moser, B., Wood, D. E., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2009 · Cited by 870
Chemokine receptors and their role in inflammation and infectious diseases
Murdoch, C., & Finn, A. (2000) · Blood · doi:10.1182/blood.v95.10.3032 · Cited by 839
Chemokine receptors: multifaceted therapeutic targets
Proudfoot, A. E. I. (2002) · Nature Reviews Immunology · doi:10.1038/nri722 · Cited by 752
Cited by
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy
Tokunaga, R., Zhang, W., Naseem, M., Puccini, A., Berger, M. D., Soni, S., McSkane, M., Baba, H., & Lenz, H.-J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.007 · Cited by 1,627
CXCR3 ligands: redundant, collaborative and antagonistic functions
Groom, J. R., & Luster, A. D. (2011) · Immunology & Cell Biology · doi:10.1038/icb.2010.158 · Cited by 1,001
Self-citationBachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.007724 · Cited by 850
Self-citationHouse, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1868 · Cited by 790
“CXCL11 binds to CXCR3 with the highest affinity, followed by CXCL10 and CXCL9 (15, 16) and notably CXCL11 binds to the CXCR3 receptor at a distinct binding site of the receptor (17), potentially leading to diverse signaling outcomes (18).”
BackgroundCXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications
Liu, M., Guo, S., Hibbert, J. M., Jain, V., Singh, N., Wilson, N. O., & Stiles, J. K. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.06.001 · Cited by 751
Interferon-γ: teammate or opponent in the tumour microenvironment?
Gocher, A. M., Workman, C. J., & Vignali, D. A. A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00566-3 · Cited by 582
Lammers, K. M., Lu, R., Brownley, J., Lu, B., Gerard, C., Thomas, K., Rallabhandi, P., Shea-Donohue, T., Tamiz, A., Alkan, S., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.023 · Cited by 540
Mikucki, M. E., Fisher, D. T., Matsuzaki, J., Skitzki, J. J., Gaulin, N. B., Muhitch, J. B., Ku, A. W., Frelinger, J. G., Odunsi, K., Gajewski, T. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8458 · Cited by 512
Self-citationThe emerging role of CXCL10 in cancer (Review)
LIU, M., GUO, S., & STILES, J. K. (2011) · Oncology Letters · doi:10.3892/ol.2011.300 · Cited by 411
Chemokines and Chemokine Receptors: Standing at the Crossroads of Immunobiology and Neurobiology
Ransohoff, R. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.010 · Cited by 371
Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling
Luttrell, L. M., Gesty-Palmer, D., & Sibley, D. R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002436 · Cited by 369
Metzemaekers, M., Vanheule, V., Janssens, R., Struyf, S., & Proost, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01970 · Cited by 328
CXCR3 ligands in disease and therapy
Van Raemdonck, K., Van den Steen, P. E., Liekens, S., Van Damme, J., & Struyf, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.11.009 · Cited by 310
Müller, M., Carter, S., Hofer, M. J., & Campbell, I. L. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01089.x · Cited by 293
Savarese, E., Chae, O.-W., Trowitzsch, S., Weber, G., Kastner, B., Akira, S., Wagner, H., Schmid, R. M., Bauer, S., & Krug, A. (2006) · Blood · doi:10.1182/blood-2005-07-2650 · Cited by 271
CXCR3 enables recruitment and site-specific bystander activation of memory CD8(+) T cells
Maurice, N. J., McElrath, M. J., Andersen-Nissen, E., Frahm, N., & Prlic, M. (2019) · Nature Communications · doi:10.1038/s41467-019-12980-2 · Cited by 117
Functional role of chemokines in liver disease models
Sahin, H., Trautwein, C., & Wasmuth, H. E. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.168 · Cited by 107
Rosenblum, J. M., Shimoda, N., Schenk, A. D., Zhang, H., Kish, D. D., Keslar, K., Farber, J. M., & Fairchild, R. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903831 · Cited by 80
“Reports demonstrating that CXCL9 and CXCL10 bind to CXCR3 in different manners and, at the least, induce different downstream signals to mediate chemotaxis suggest that different signaling mechanisms may influence the costimulatory nature of the receptor (48, 49).”
BackgroundKoupourtidou, C., Schwarz, V., Aliee, H., Frerich, S., Fischer-Sternjak, J., Bocchi, R., Simon-Ebert, T., Bai, X., Sirko, S., Kirchhoff, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46625-w · Cited by 48
Metadata
- Authors
- Colvin, R. A., Campanella, G. S. V., Sun, J., & Luster, A. D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-07
- Volume
- 279
- Issue
- 29
- Pages
- 30219-30227
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2046230726
- Cited by
- 274
- References
- 51
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.